Mirati Therapeutics, Inc.
MRTX
Pozycja w akcjach
#4926
Mirati Therapeutics, Inc. is a U.S.-based biotechnology firm operating at the... Mirati Therapeutics, Inc. is a U.S.-based biotechnology firm operating at the clinical stage, committed to identifying and developing treatments that target the genetic and immunological factors driving cancer progression. Its pipeline features MRTX849, a KRAS G12C inhibitor currently undergoing Phase 1/2 clinical trials for a range of malignancies, including non-small cell lung, colorectal, and pancreatic cancers. Additionally, the company is advancing Sitravatinib, an investigational broad-spectrum kinase inhibitor, which has reached Phase 3 clinical trials specifically for non-small cell lung cancer. Mirati also has a KRAS G12D inhibitor program in its preclinical development phase. The company has forged a collaboration and licensing agreement with BeiGene, Ltd. for the development, manufacturing, and commercialization of sitravatinib. Established in 1995, Mirati Therapeutics, Inc. maintains its headquarters in San Diego, California.
Cena akcji
$58.70
Ostatnia synchronizacja: 2024-01-23
Kapitalizacja rynkowa
$2.98B
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
0.00%
Kraj
US
Handel Mirati Therapeutics, Inc. (MRTX)
Kategoria
Healthcare
Historia ceny akcji dla Mirati Therapeutics, Inc. (MRTX)
Najwyższa cena zamknięcia: $58.94 dnia 2024-01-01
Najniższa cena zamknięcia: $8.67 dnia 2013-07-01
Najniższa cena zamknięcia: $8.67 dnia 2013-07-01
Historia cen akcji firmy Mirati Therapeutics, Inc. od 2013 do 2026
Roczna wydajność ceny akcji
| Rok | Wydajność |
|---|---|
| 2024 | 2.02% |
| 2023 | 12.06% |
| 2022 | -63.56% |
| 2021 | -39.15% |
| 2020 | 103.16% |
| 2019 | 189.49% |
| 2018 | 132.29% |
| 2017 | 218.41% |
| 2016 | -84.08% |
| 2015 | 98.82% |
| 2014 | 1.02% |
| 2013 | 0.00% |
Cena akcji podobnych firm lub konkurencji
| Firma | Cena akcji | Zmiana 1r% | Kraj |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.09 | -4.30% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
